Literature DB >> 1316323

Adenosarcoma of the uterus: a Gynecologic Oncology Group clinicopathologic study of 31 cases.

T Kaku1, S G Silverberg, F J Major, A Miller, B Fetter, M F Brady.   

Abstract

We report on the clinical and pathologic findings in 31 cases of adenosarcoma of the uterus subjected to hysterectomy and staging laparotomy. Nine of 30 patients (30%) have had recurrent tumor and six of 30 (20%) have already died of tumor in a relatively short follow-up period (mean, 38.3 months). Seventeen of 31 cases were diagnosed as adenosarcoma with sarcomatous overgrowth (SO). Ten of these 17 with SO contained focal or extensive rhabdomyosarcoma. In six cases, extrauterine spread was identified as follows (two patients had two sites each): vaginal involvement (two cases), pelvic lymph node metastases (two), positive peritoneal cytologic findings (two), parametrial invasion (one), and ovarian metastasis (one). Extrauterine spread (stage III) (p less than 0.001) and myometrial invasion (p = 0.04) were associated with higher rates of recurrence. The presence of lymphatic and/or vascular invasion, SO, and rhabdomyosarcomatous differentiation also indicated poor prognosis but did not attain statistical significance. Based on this experience, staging laparotomy including peritoneal cytology is suggested in cases of clinical stages I and II adenosarcoma. The differential diagnosis of these tumors is also discussed.

Entities:  

Mesh:

Year:  1992        PMID: 1316323

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  29 in total

1.  Clinical benefit of trabectedin in uterine adenosarcoma.

Authors:  Brett A Schroeder; Eve T Rodler; Elizabeth T Loggers; Seth M Pollack; Robin L Jones
Journal:  Med Oncol       Date:  2013-02-28       Impact factor: 3.064

2.  Extragenital Müllerian adenosarcoma with pouch of Douglas location.

Authors:  Tito S Patrelli; Enrico M Silini; Salvatore Gizzo; Roberto Berretta; Laura Franchi; Elena Thai; Adolf Lukanovic; Giovanni B Nardelli; Alberto Bacchi Modena
Journal:  BMC Cancer       Date:  2011-05-15       Impact factor: 4.430

3.  Significance of lymph node metastasis on survival of women with uterine adenosarcoma.

Authors:  Hiroko Machida; Michael J Nathenson; Tsuyoshi Takiuchi; Crystal L Adams; Jocelyn Garcia-Sayre; Koji Matsuo
Journal:  Gynecol Oncol       Date:  2017-01-18       Impact factor: 5.482

4.  Uterine adenosarcoma: an analysis on management, outcomes, and risk factors for recurrence.

Authors:  Amy Carroll; Pedro T Ramirez; Shannon N Westin; Pamela T Soliman; Mark F Munsell; Alpa M Nick; Kathleen M Schmeler; Ann H Klopp; Nicole D Fleming
Journal:  Gynecol Oncol       Date:  2014-10-28       Impact factor: 5.482

Review 5.  Uterine Adenosarcoma: a Review.

Authors:  Michael J Nathenson; Vinod Ravi; Nicole Fleming; Wei-Lien Wang; Anthony Conley
Journal:  Curr Oncol Rep       Date:  2016-11       Impact factor: 5.075

6.  Uterine Adenosarcoma with Sarcomatous Overgrowth and Rhabdoid Features: A Rare Case.

Authors:  Sameera Rashid; Mohammed Akhtar
Journal:  Saudi J Med Med Sci       Date:  2022-01-17

7.  [Uterine sarcoma treatment].

Authors:  G Köhler
Journal:  Pathologe       Date:  2009-07       Impact factor: 1.011

8.  Extragenital adenosarcoma: a case report, review of the literature, and management discussion.

Authors:  Gloria S Huang; Rebecca C Arend; Antoinette Sakaris; Tiffany M Hebert; Gary L Goldberg
Journal:  Gynecol Oncol       Date:  2009-08-26       Impact factor: 5.482

9.  Adenosarcoma of the uterus: a case report.

Authors:  Sivekar Tinar; Salim Sehirali; M Murat Inal; Yusuf Yildrim; Esin Celik; Seyran Yigit
Journal:  MedGenMed       Date:  2004-01-12

10.  Genomewide copy number analysis of Müllerian adenosarcoma identified chromosomal instability in the aggressive subgroup.

Authors:  Jen-Chieh Lee; Tzu-Pin Lu; Chun A Changou; Cher-Wei Liang; Hsien-Neng Huang; Alexandra Lauria; Hsuan-Ying Huang; Chin-Yao Lin; Ying-Cheng Chiang; Ben Davidson; Ming-Chieh Lin; Kuan-Ting Kuo
Journal:  Mod Pathol       Date:  2016-06-03       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.